Product Images Propafenone Hydrochloride

This document appears to be a chart or graph representing the proportion of patients without an event over time in a study involving Propafenone ER (extended-release) medication. The chart shows two groups: one receiving Propafenone ER 425 mg bid and the other a placebo. There is also mention of a group receiving Propafenone ER 225 mg bid. The study lasted from day 1 to day 300, with a patient dropout on day 273. There was a 0% decline in the Kaplan el curvs due to 1 patient experiencing an event on day 291.*

Propafenone Hydrochloride Extended-Release Capsules, manufactured by TWi Pharmaceuticals USA, contain 225 mg of propafenone hydrochloride USP. The recommended dosage information should be followed as per the prescribing information. The bottle should not be accepted if the seal is broken or missing. These capsules should be stored in a container defined as per the USP between a temperature of 20 to 25°C. The manufacturer and NDC number are provided on the package.*

Propafenone Hydrochloride Extended-Release Capsules, USP are a medication that contains 325 mg of propafenone hydrochloride, USP per capsule. The usual dosage should be obtained from the accompanying prescribing information. The capsules should not be accepted if the seal over the bottle opening is broken or missing. They should be stored at room temperature between 20°C to 25°C. The capsules should be dispensed in a container as defined in the USP. These capsules are manufactured by TWi Pharmaceuticals USA, Inc. in Paramus, NJ, and TWi Pharmaceuticals, Inc. in Taoyuan City, Taiwan, with NDC 24979-086-04.*